- Home
- THCH vs CLYM Comparison
THCH vs CLYM Comparison
Compare THCH & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- CLYM
- Stock Information
- Founded
- THCH 2018
- CLYM 2018
- Country
- THCH China
- CLYM United States
- Employees
- THCH N/A
- CLYM N/A
- Industry
- THCH Blank Checks
- CLYM
- Sector
- THCH Finance
- CLYM
- Exchange
- THCH Nasdaq
- CLYM NYSE
- Market Cap
- THCH 73.0M
- CLYM 83.1M
- IPO Year
- THCH N/A
- CLYM 2021
- Fundamental
- Price
- THCH $2.63
- CLYM $1.19
- Analyst Decision
- THCH
- CLYM
- Analyst Count
- THCH 0
- CLYM 0
- Target Price
- THCH N/A
- CLYM N/A
- AVG Volume (30 Days)
- THCH 9.8K
- CLYM 125.8K
- Earning Date
- THCH 06-04-2025
- CLYM 05-19-2025
- Dividend Yield
- THCH N/A
- CLYM N/A
- EPS Growth
- THCH N/A
- CLYM N/A
- EPS
- THCH N/A
- CLYM N/A
- Revenue
- THCH $190,593,087.00
- CLYM N/A
- Revenue This Year
- THCH N/A
- CLYM N/A
- Revenue Next Year
- THCH N/A
- CLYM N/A
- P/E Ratio
- THCH N/A
- CLYM N/A
- Revenue Growth
- THCH N/A
- CLYM N/A
- 52 Week Low
- THCH $2.15
- CLYM $1.05
- 52 Week High
- THCH $6.00
- CLYM $10.23
- Technical
- Relative Strength Index (RSI)
- THCH 43.75
- CLYM N/A
- Support Level
- THCH $2.61
- CLYM N/A
- Resistance Level
- THCH $2.84
- CLYM N/A
- Average True Range (ATR)
- THCH 0.13
- CLYM 0.00
- MACD
- THCH 0.01
- CLYM 0.00
- Stochastic Oscillator
- THCH 48.94
- CLYM 0.00
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. It is also the operator and developer of Popeyes brand in Mainland China. The firm has two reportable segments; Tim Hortons which generates key revenue, and Popeyes. The company's revenue is derived from its operations in the PRC.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.